ST. LOUIS, June 07, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will share the latest innovations to its Niobe® ES magnetic navigation system and supporting clinical evidence at Cardiostim-EHRA Europace 2016, the 20th world congress in cardiac electrophysiology (EP) and cardiac techniques, taking place June 8-11 in Nice, France. The congress brings together more than 5,600 industry practitioners from over 125 countries to discuss the evolution of technologies and research advancements in the treatment of rhythm disorders.
“Cardiostim represents an important part of our event schedule every other year, as the largest attended, biennial scientific sessions pertaining to cardiac EP in Europe,” said William C. Mills, Stereotaxis Chief Executive Officer. “This year, we have enhanced the ‘Stereotaxis experience’ for participants through a modeled beating heart phantom that enables them to see and feel the mechanics of our magnetic navigation and latest automation technologies around effective lesion creation, the benefits of which will be reinforced by expert users sharing their most recent clinical findings with our system.”
In exhibit space C12, Stereotaxis will highlight the latest innovations to its Niobe ES system, including the next generation user interface, which includes new features such as improved catheter tip-to-tissue contact confirmation based on bipolar impedance information. The Company also will share development progress for product enhancements related to ventricular tachycardia ablation and unveil its newly developed, software-based simulation platform for physician training.
On Friday, June 10, during a scientific session dedicated to remote magnetic navigation, several physicians representing the Society of Cardiac Robotic Navigation will speak to the role of the Niobe system in their EP practice. These include Dr. Philippe Ricard of Clinique Saint George in Nice, who will share new developments around ablation of atrial fibrillation (AF) using the Niobe system, and Dr. Dirk Bastian of Paracelsus Medical Center in Germany, which recently released study results demonstrating significantly reduced fluoroscopy times for patients undergoing ablation for persistent AF with the Niobe system. Additionally, Dr. Bruno Schwagten (ZNA Middelheim Hospital, Belgium) will share evidence of the Niobe system’s ability to reduce operator fatigue; Dr. Gery Tomassoni (Lexington Cardiology at Central Baptist, Kentucky) will highlight the clinical benefits of the Vdrive® robotic navigation system and its remotely directed disposables; and Dr. Tamas Szili-Torok (Erasmus Medical Center, The Netherlands) will provide a comparison of magnetic navigation and manual techniques in ventricular tachycardia ablation.
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch® Solution includes the Niobe® magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive® robotic navigation system and consumables.
The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its continued listing on the NASDAQ Capital Market, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
Martin C. Stammer
Chief Financial Officer
Todd Kehrli / Jim ByersMKR Group, Inc.